Recombinant Vaccines Market Overview by Recent Opportunities, Growth Size, Regional Analysis and Forecasts to 2027

The global recombinant vaccines market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Recombinant vaccines are genetically engineered vaccines. They are produced in the laboratory while eradicating the danger of infectious viral antigen which assures vaccine effectiveness and safety. Additionally, these vaccines are developed by the appliance of recombinant deoxyribonucleic acid technology and by using an expression system such as yeast, bacteria, mammalian cells, among others to precise the antigenic protein component. The major factor driving the demand for recombinant vaccines is the increasing prevalence of infectious diseases across the globe.

For instance, in December 2019, Merck & Co., Inc. announced the approval of Ervebo from the US Food and Drug Administration (FDA). It is intended for the prevention of Ebola virus disease (EVD) that is caused by Zaire ebolavirus in individuals 18 years of age and older. Additionally, in January 2022, Pfizer Inc. announced a new research, development and commercialization collaboration with BioNTech SE. The collaboration was aimed to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV).

To Request a Sample of our Report on Recombinant Vaccines Market: https://www.omrglobal.com/request-sample/recombinant-vaccines-market

Some major players in the market include GlaxoSmithKline plc, Sanofi S.A., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in February 2021, Sanofi announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over with GSK. The study was aimed to select the most appropriate antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate.

Market Coverage

• The market number available for - 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

Segment Covered-

· By Type

· By Indication

· By Route of Administration

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- GlaxoSmithKline plc, Sanofi S.A., and Novartis International AG, among others.

(Get 15% Discount on Buying this Report)

A full Report of Recombinant Vaccines Market is Available @ https://www.omrglobal.com/industry-reports/recombinant-vaccines-market

Global Recombinant Vaccines Market Report by Segment

By Type

• Live-attenuated Vaccines

• Subunit Vaccines

By Indication

• HPV

• Cancer

• Hepatitis B

• Herpes Zoster

• Others

By Route of Administration

• Oral

• Parenteral

Global Recombinant Vaccines Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.